Table 4. Correlation between preoperative serum tumor makers and major clinicopathological traits in the validation cohort.
| Patient characteristics | Cases n (%) | CA125 (+)n (%) | P | CA19-9 (+)n (%) | P | CEA (+)n (%) | P | ||
|---|---|---|---|---|---|---|---|---|---|
| Gender | Male | 454 (68.0) | 171 (37.7) | 0.007 | 97 (21.4) | 0.278 | 109 (24.0) | <0.001 | |
| Female | 214 (32.0) | 104 (48.6) | 38 (17.8) | 24 (11.2) | |||||
| Age (ys) | <60 | 339 (50.7) | 142 (41.9) | 0.701 | 69 (20.4) | 0.925 | 58 (17.1) | 0.066 | |
| ≥60 | 329 (49.3) | 133 (40.4) | 66 (20.1) | 75 (22.8) | |||||
| Tumor location | Upper | 187 (28.0) | 78 (41.7) | 0.374 | 46 (24.6) | 0.293 | 46 (24.6) | 0.122 | |
| Middle | 97 (14.5) | 47 (48.5) | 20 (20.6) | 21 (21.6) | |||||
| Lower | 373 (55.8) | 145 (38.9) | 68 (18.2) | 63 (16.9) | |||||
| Whole | 11 (1.6) | 5 (45.5) | 1 (9.1) | 3 (27.3) | |||||
| Tumor size (cm) | ≤2 | 81 (12.1) | 24 (29.6) | <0.001 | 7 (8.6) | 0.001 | 12 (14.8) | 0.004 | |
| 2-5 | 300 (44.9) | 101 (33.7) | 56 (18.7) | 47 (15.7) | |||||
| 5-8 | 227 (34.0) | 117 (51.5) | 56 (24.7) | 61 (26.9) | |||||
| >8 | 60 (9.0) | 33 (55.0) | 16 (26.7) | 13 (21.7) | |||||
| Macroscopic type | Type-0 | 90 (13.5) | 21 (23.3) | <0.001 | 7 (7.8) | 0.002 | 8 (8.9) | 0.003 | |
| Type-1 | 29 (4.3) | 16 (55.2) | 4 (13.8) | 4 (13.8) | |||||
| Type-2 | 273 (40.9) | 108 (39.6) | 56 (20.5) | 56 (20.5) | |||||
| Type-3 | 225 (33.7) | 98 (35.6) | 57 (25.3) | 49 (21.8) | |||||
| Type-4 | 51 (7.6) | 32 (62.7) | 11 (21.6) | 16 (31.4) | |||||
| Differentiation grade | Well | 5 (0.7) | 3 (60.0) | 0.452 | 0 (0.0) | 0.131 | 0 (0.0) | 0.944 | |
| Moderate | 91 (13.6) | 33 (36.3) | 14 (15.4) | 19 (20.9) | |||||
| Poor | 572 (85.6) | 239 (41.8) | 121 (21.2) | 114 (19.9) | |||||
| pT stage | T1 | 122 (18.3) | 35 (28.7) | <0.001 | 12 (9.8) | <0.001 | 14 (11.5) | 0.017 | |
| T2 | 87 (13.0) | 30 (34.5) | 14 (16.1) | 19 (21.8) | |||||
| T3 | 106 (15.9) | 41 (38.7) | 14 (13.2) | 19 (17.9) | |||||
| T4 | 353 (52.8) | 169 (47.9) | 95 (26.9) | 81 (22.9) | |||||
| pN stage | N0 | 206 (30.8) | 59 (28.6) | 0.001 | 15 (7.3) | <0.001 | 23 (11.2) | 0.001 | |
| N1 | 115 (17.2) | 56 (48.7) | 29 (25.2) | 29 (25.2) | |||||
| N2 | 114 (17.1) | 55 (48.2) | 24 (21.1) | 24 (21.1) | |||||
| N3a | 145 (21.7) | 61 (42.1) | 42 (29.0) | 33 (22.8) | |||||
| N3b | 88 (13.2) | 44 (50.0) | 25 (28.4) | 24 (27.3) | |||||
| M stage | M0 | 629 (94.2) | 252 (40.1) | 0.020 | 126 (20.0) | 0.646 | 119 (18.9) | 0.010 | |
| M1 | 39 (5.8) | 23 (59.0) | 9 (23.1) | 14 (35.9) | |||||
| pTNM stage | I | 141 (21.1) | 39 (27.7) | <0.001 | 12 (8.5) | <0.001 | 19 (13.5) | 0.005 | |
| II | 151 (22.6) | 54 (35.8) | 19 (12.6) | 28 (18.5) | |||||
| III | 337 (50.4) | 159 (47.2) | 95 (28.2) | 72 (21.4) | |||||
| IV | 39 (5.8) | 23 (59.0) | 9 (23.1) | 14 (35.9) | |||||